Federica Morano Selected Research

Microsatellite Instability

1/2021	The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors.
1/2021	Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors.
1/2021	Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors.
1/2020	Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial.
1/2020	Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden.
12/2019	Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer.
11/2019	Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Federica Morano Research Topics

Disease

41	Colorectal Neoplasms (Colorectal Cancer) 12/2023 - 01/2016
34	Neoplasms (Cancer) 04/2024 - 09/2012
13	Stomach Neoplasms (Stomach Cancer) 06/2023 - 01/2017
9	Disease Progression 12/2023 - 01/2018
8	Neoplasm Metastasis (Metastasis) 04/2024 - 01/2016
7	Microsatellite Instability 01/2021 - 11/2019
5	Adenocarcinoma 01/2024 - 01/2019
3	Biliary Tract Neoplasms (Biliary Tract Cancer) 05/2024 - 01/2022
3	Pseudomyxoma Peritonei 12/2023 - 01/2019
3	Neutropenia 01/2023 - 01/2021
3	Rectal Neoplasms (Rectal Cancer) 01/2023 - 01/2013
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 12/2023 - 01/2022
2	Amnesia (Dissociative Amnesia) 01/2023 - 01/2018
2	Carcinoma (Carcinomatosis) 11/2021 - 01/2017
2	Inflammation (Inflammations) 01/2021 - 01/2020
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2024
1	Diarrhea 01/2024
1	Protein Deficiency 11/2023
1	Neoplasm Micrometastasis 01/2023
1	Triple Negative Breast Neoplasms 01/2023
1	Exanthema (Rash) 11/2022
1	Anemia 11/2022
1	Cholangiocarcinoma 10/2022
1	Turcot syndrome 01/2022
1	Myocardial Infarction 01/2022
1	Febrile Neutropenia 01/2022
1	Critical Illness (Critically Ill) 01/2020
1	Death (Near-Death Experience) 01/2020
1	Glioblastoma (Glioblastoma Multiforme) 01/2019
1	Necrosis 01/2018
1	Infarction (Infarctions) 01/2018

Drug/Important Bio-Agent (IBA)

14	Biomarkers (Surrogate Marker)IBA 04/2024 - 01/2017
12	Fluorouracil (Carac)FDA LinkGeneric 01/2024 - 01/2018
11	Panitumumab (Vectibix)FDA Link 12/2023 - 01/2016
9	Leucovorin (Folinic Acid)FDA Link 01/2024 - 09/2019
8	Bevacizumab (Avastin)FDA Link 12/2023 - 01/2018
8	Immune Checkpoint InhibitorsIBA 01/2023 - 01/2020
7	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2024 - 01/2017
6	Irinotecan (Camptosar)FDA LinkGeneric 01/2024 - 01/2017
6	ErbB Receptors (EGF Receptor)IBA 01/2023 - 01/2019
5	Capecitabine (Xeloda)FDA Link 12/2023 - 01/2017
5	Temozolomide (Temodar)FDA LinkGeneric 10/2022 - 12/2017
5	Cetuximab (Erbitux)FDA Link 11/2021 - 01/2017
4	Trastuzumab (Herceptin)FDA Link 06/2023 - 01/2018
4	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 01/2019
3	Gemcitabine FDA Link 05/2024 - 01/2024
3	Cisplatin (Platino)FDA LinkGeneric 05/2024 - 01/2020
3	atezolizumabIBA 01/2023 - 07/2020
3	RNA (Ribonucleic Acid)IBA 01/2023 - 11/2019
3	PlatinumIBA 10/2022 - 01/2017
3	Monoclonal AntibodiesIBA 11/2021 - 05/2017
3	Paclitaxel (Taxol)FDA LinkGeneric 03/2019 - 01/2017
2	pertuzumabIBA 01/2023 - 01/2021
2	MethyltransferasesIBA 10/2022 - 01/2020
2	avelumabIBA 11/2021 - 10/2021
2	Epidermal Growth Factor (EGF)IBA 01/2021 - 09/2019
2	RamucirumabIBA 03/2019 - 01/2018
1	folfirinoxIBA 01/2024
1	130-nm albumin-bound paclitaxelIBA 01/2024
1	Metformin (Glucophage)FDA LinkGeneric 12/2023
1	lanreotide (Somatuline)FDA Link 12/2023
1	CholesterolIBA 12/2023
1	Fatty Acid Synthases (Fatty Acid Synthase)IBA 06/2023
1	AntibodiesIBA 01/2023
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2023
1	olaparibIBA 01/2023
1	Trinitrotoluene (TNT)IBA 01/2023
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 10/2022
1	IpilimumabIBA 10/2022
1	NivolumabIBA 10/2022
1	pembrolizumabIBA 01/2022
1	Doxycycline (Periostat)FDA LinkGeneric 07/2021
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	Lapatinib (GW572016)FDA Link 01/2021
1	Circulating Tumor DNAIBA 01/2021
1	Everolimus FDA Link 01/2021
1	SynaptophysinIBA 01/2021
1	Programmed Cell Death 1 ReceptorIBA 01/2020
1	GuanineIBA 01/2020
1	Docetaxel (Taxotere)FDA Link 01/2020
1	Proteins (Proteins, Gene)FDA Link 01/2019
1	EnzymesIBA 01/2019
1	Cytotoxins (Cytolysins)IBA 01/2019
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019
1	SilverIBA 05/2017

Therapy/Procedure

25	Therapeutics 06/2023 - 12/2017
20	Drug Therapy (Chemotherapy) 05/2024 - 01/2016
4	Neoadjuvant Therapy 04/2024 - 01/2013
3	Immunotherapy 01/2022 - 01/2020
2	Continuity of Patient Care 11/2023 - 01/2023
2	Radiotherapy 11/2023 - 01/2023
2	Adjuvant Chemotherapy 01/2023 - 12/2019
1	Hyperthermic Intraperitoneal Chemotherapy 01/2023
1	Secondary Prevention 01/2023
1	Cytoreduction Surgical Procedures 01/2023
1	Consolidation Chemotherapy 01/2023
1	Retreatment 01/2022
1	Duration of Therapy 01/2021
1	Palliative Care (Palliative Therapy) 01/2020
1	Precision Medicine 11/2019